Latest Trastuzumab Stories
Current testing protocols for HER2 amplification may exclude thousands of patients who actually have HER2 gene amplification, delaying or preventing them from receiving potentially life-saving
The future looks bright for patients with HER2-positive breast cancer. A paper published in the October 6, 2011 issue of the New England Journal of Medicine (NEJM), shows that new treatment regimens, providing a lower risk of cardio toxicity, are an acceptable and effective option for patients.
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease.
- Withering but not falling off, as a blossom that persists on a twig after flowering.